



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/701,871
Filing Date	11/5/2003
First Named Inventor	Renfeng Guo, et al.
Art Unit	1645
Examiner Name	Devi
Attorney Docket Number	UM-08443

Sheet	1	of	3
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SD	1	Mandecki et al., "Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia," PNAS U S A. Jun;82(11):3543 7(1985)	
SD	2	Reidemann et al., "Increased C5a receptor expression in sepsis," (2002) J. Clin. Invest. 110:101-108	
SD	3	Solomkin et al., "Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation," Surgery 90:319-327, (1981)	
SD	4	Van Epps, et al., "Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a," J. Immunol. 150:246-252 (1993)	
SD	5	Ward and Becker, "The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase," J. Exp. Med. 127:693-709 (1968)	
SD	6	Olson et al., "The role of C5 in septic lung injury," Ann. Surg. 202:771-776 (1985)	
SD	7	Wong et al., "Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a," (1998) J. Med. Chem. 41,3417-3425	
SD	8	Mollison et al., (1992) FASEB J. 6,A2058	
SD	9	Drapeau et al., "Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects," (1993) Biochem. Pharmacol. 45,1289-1299	
SD	10	Konteatis et al., "Development of C5a receptor antagonists. Differential loss of functional responses," (1994) J. Immunol. 153,4200-4205	

Examiner Signature	/S. Devi/	Date Considered	12/28/2006
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/701,871
Filing Date	11/5/2003
First Named Inventor	Renfeng Guo, et al.
Art Unit	1645
Examiner Name	Devi
Attorney Docket Number	UM-08443

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SD	11	Woodruff et al., "Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes," Inflammation 25, 171-7. (2001)	
SD	12	Haynes et al., "Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist," Biochem Pharmacol 60, 729-33. (2000)	
SD	13	Strachan et al., "A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats," J Immunol 164, 6560-5. (2000)	
SD	14	Paczkowski et al., "Pharmacological characterization of antagonists of the C5a receptor," Br J Pharmacol 128, 1461-6. (1999)	
SD	15	Finch et al., J Med Chem 42, 1965-74. (1999)	
SD	16	Strachan et al., "Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist," Br J Pharmacol 134, 1778-86. (2001)	
SD	17	Short et al., "Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat," (1999) Br. J. Pharmacol. 126,551-554	
SD	18	Mulligan et al., "Requirement and role of C5a in acute lung inflammatory injury in rats," (1996) J. Clin. Invest. 98,503-512	
SD	19	Larsen et al., "The pulmonary response of C5 sufficient and deficient mice to immune complexes," (1981) Am. Rev. Respir. Dis. 123,434-439	
SD	20	Koch et al., (1997) Shock 7,42-48	

Examiner Signature	/s. Devi/	Date Considered	12/28/2006
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/701,871
Filing Date	11/5/2003
First Named Inventor	Renfeng Guo, et al.
Art Unit	1645
Examiner Name	Devi
Attorney Docket Number	UM-08443

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SD	21	Short et al., "Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat," (1999) Br. J. Pharmacol. 128,511-514	
SD	22	Goya et al., "Immunologic assessment of host defense impairment in patients with septic multiple organ failure: relationship between complement activation and changes in neutrophil function," (1994) Surgery 115,145-155	
SD	23	Hecke et al., "Circulating complement proteins in multiple trauma patients—correlation with injury severity, development of sepsis, and outcome," (1997) Crit. Care Med. 25,2015-2024	
SD	24	Czermak et al., "Protective effects of C5a blockade in sepsis," (1999) Nature Med.. 5,788-792	

Examiner Signature	/s. Devi/	Date Considered	12/28/2006
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.